Putaminal y‐Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease

Background Motor response to dopaminergic therapy is a characteristic of patients with Parkinson's disease (PD). Whether nondopaminergic neurotransmitters contribute to treatment response is uncertain. Objectives The aim of this study is to determine whether putaminal y‐aminobutyric acid (GABA)...

Full description

Saved in:
Bibliographic Details
Published inMovement disorders Vol. 36; no. 9; pp. 2187 - 2192
Main Authors Seger, Aline D., Farrher, Ezequiel, Doppler, Christopher E.J., Gogishvili, Ana, Worthoff, Wieland A., Filss, Christian P., Barbe, Michael T., Holtbernd, Florian, Shah, N. Jon, Fink, Gereon R., Sommerauer, Michael
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.09.2021
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Motor response to dopaminergic therapy is a characteristic of patients with Parkinson's disease (PD). Whether nondopaminergic neurotransmitters contribute to treatment response is uncertain. Objectives The aim of this study is to determine whether putaminal y‐aminobutyric acid (GABA) levels are associated with dopaminergic motor response. Methods We assessed putaminal GABA levels in 19 PD patients and 13 healthy controls (HCs) utilizing ultra‐high field proton magnetic resonance spectroscopy. Motor performance was evaluated using the Movement Disorder Society—Unified Parkinson's Disease Rating Scale, Part III, in the ON and OFF states. Statistical analysis comprised group comparisons, correlation analysis, and multiple linear regression. Results In PD, GABA levels were significantly higher compared to HCs (1.50 ± 0.26 mM vs. 1.26 ± 0.31 mM, P = 0.022). Furthermore, GABA levels were independent predictors of absolute and relative dopaminergic treatment response. Conclusions Our findings indicate that elevated putaminal GABA levels are associated with worse dopaminergic response in PD, emphasizing the essential role of nondopaminergic neurotransmitters in motor response. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Bibliography:All authors have no financial disclosures to declare and no conflicts of interests with regard to this manuscript.
Else Kröner‐Fresenius‐Stiftung (grant number 2019_EKES.02); Koeln Fortune Program, Faculty of Medicine, University of Cologne (grant number 453/2018); Clinician Scientist Program (CCSP), Faculty of Medicine, University of Cologne, funded by the German Research Foundation (DFG, FI 773/15‐1); Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Project‐ID 431549029, SFB 1451; Shota Rustaveli National Science Foundation, Tbilisi, Georgia (grant number JFZ_18_02).
Relevant conflicts of interest/financial disclosures
Funding agencies
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0885-3185
1531-8257
DOI:10.1002/mds.28674